AKT1 and breast cancer: YTHDF1 increases RPN2 expression through m6A modification, which subsequently activates the PI3K/AKT/mTOR signaling pathway, thereby endowing cells with greater survival capabilities and increasing cisplatin resistance.24 Under conditions of low YTHDC1 expression, BC cells exhibit even higher resistance to cisplatin.